|drug1841||Hypofractionated intensity modulated radiotherapy Wiki||1.00|
There is one clinical trial.
This is a single arm Phase I study of de-intensified hypofractionated radiation therapy for favorable human papilloma virus-associated oropharynx cancer. It will evaluate the tolerability of a de-intensified hypofractionated radiation therapy regimen completed in 3 weeks (with equivalent biologically effective dose to 60 Gy in 30 fractions) with concurrent weekly cisplatin.
Description: CTCAE v5.0Measure: Clinician-reported acute toxicities Time: 0-3 months
Description: CTCAE v5.0Measure: Clinician-reported late toxicities Time: 3-12 months
Description: MD Anderson Dysphagia Inventory (MDADI): 20-100, higher scores mean better quality of lifeMeasure: Swallowing-related patient-reported quality of life Time: 1-12 months
Description: University of Washington QOL questionnaire (UW-QOL): 0-100, higher scores mean better quality of lifeMeasure: Head and neck patient-reported quality of life Time: 1-12 months
Description: University of Michigan Xerostomia questionnaire (XQ): 0-100, higher scores mean worse quality of lifeMeasure: Xerostomia-related patient-reported quality of life Time: 1-12 months
Description: EuroQol-5 dimensions (EQ-5D-5L): 1-5, higher scores mean worse quality of lifeMeasure: General patient-reported quality of life Time: 1-12 months
Description: Dependence on tube feeds defined as daily use of ≥2 nutritional supplements per day via the feeding tube at the time of evaluationMeasure: Feeding tube dependence Time: 1-12 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports